Latest news with #ThomasBurns
San Francisco Chronicle
25-07-2025
- General
- San Francisco Chronicle
Letters: Prop 13 encourages older homeowners to stay put. Here's a way around that
Regarding 'What it's like to live in the Bay Area neighborhood that's aging the fastest' (The Graying Bay, July 15): By limiting property tax increases to the rate of inflation for homeowners, Proposition 13 contributed to the stability of many neighborhoods like Thousand Oaks in Berkeley, where I've lived for 50 years. The downside to Prop 13 is that it provides an incentive for retired couples and surviving spouses to remain in homes that may be larger than they need. One idea for encouraging older residents to move out and make way for younger families would be to eliminate the capital gains tax on homes that are full-time residences. Often, the home is the largest share of retirees' savings. Unlocking this capital would permit much greater flexibility in the plans of retirees. Thomas Burns, Berkeley Be careful on e-bikes Regarding 'A 'phenomenal' way for older adults to get exercise' (The Graying Bay, July 20): I agree that riding electric bikes is a good way for older people to exercise. Caution is wise. As American College of Surgeons members have noted, older adults, who may have been less skilled at riding a bicycle, are more likely to hit obstacles on bike paths and other fixed structures. The higher speeds and heavy batteries of electric bikes pose special risks, especially for losing control when riding downhill. That's why the e-bike injury pattern more closely resembles motorcycles than bicycles. Dr. John Maa, governor, American College of Surgeons, San Francisco Protect S.F. pedestrians Regarding 'Electric scooter rider fatally strikes 77-year-old pedestrian in San Francisco' (San Francisco, July 21): I am older than the man who died, and I have been nearly hit by scooters, bicycles (electric and manual) in San Francisco on several occasions. Not in the street — on the sidewalk. I once watched a man on an electric scooter zoom by a police officer on the 24th Street BART Station plaza. When I asked the officer why the police don't stop this dangerous practice, he looked surprised and said, 'Oh, there are too many.' Signs on the Embarcadero direct electric scooters and electric bikes to stay off the promenade and on the bike path. I have never seen this enforced and am afraid to walk by the bay in my city. Maybe the mayor and the police department can take some time off from corralling homeless people and protect us pedestrians from injury and death. Catherine Cusic, San Francisco Riding in the blind Regarding 'Long strange trip: Muni just unveiled new psychedelic buses in San Francisco' (Total SF, July 22): One of the great pleasures of riding Muni is looking out the window at this wonderful city. While the outside of these buses and trains may look like an 'acid flashback' and are a colorful addition to our streets, passengers suffer blurry vision as they gaze out the windows. I avoid riding in Muni vehicles with covered windows. It's advertising that seeks to beat you over the head with its message. I tend to look away from the blight passing by and make a mental note not to patronize that business. Barry Hermanson, San Francisco Service is a gift Regarding 'The toughest job I've ever loved: Why the Peace Corps matters even more in the Trump era' (U.S. & World, July 16): At a time when the White House scoffs at soft diplomacy and the Peace Corps' fate hangs in the balance, thank you for publishing Jill Tucker's moving description of her experience. It is fitting that Tucker's story was published in the Bay Area. The first group of Peace Corps volunteers was trained at UC Berkeley, and it has sent more volunteers than any other university. While the White House may not understand what motivates the desire to help those less fortunate, most who serve understand the reward of the goodbye from Nilton, one of Tucker's young students in Cape Verde: 'My eyes will never forget your face. My ears will never forget our voice and my mind will never forget what you taught me.'
Yahoo
27-06-2025
- Business
- Yahoo
Glaukos gains EU certification for iStent infinite and other MIGS devices
Glaukos has secured European Union Medical Device Regulation (EU-MDR) certification for its iStent infinite, along with other micro-invasive glaucoma surgery (MIGS) technologies, including the iStent inject W. According to the company, its iStent trabecular micro-bypass stenting platform predominantly involves the insertion of micro-scale surgical devices intended to minimise intraocular pressure (IOP) with the restoration of pathways of the natural aqueous humor outflow for individuals with glaucoma. Known for creating two patent bypass pathways via the trabecular meshwork, the iStent inject W claims to be one of the smallest medical devices to be implanted in the body of a human. Its design allows for multi-directional flow through Schlemm's canal, offering a micro-invasive approach to glaucoma treatment. The iStent infinite Trabecular Micro-Bypass System Model iS3 is intended to minimise IOP in adults with primary open-angle glaucoma where prior treatments have failed. As the first standalone micro-invasive implantable alternative, the iStent infinite is said to have been tailored to maximise outflow with minimal disruption to natural anatomy, occupying 3% of Schlemm's canal. Glaukos CEO and chairman Thomas Burns said: "We are pleased to receive these important regulatory clearances for our leading trabecular micro-bypass stenting devices, marking our company's first approvals under the new EU regulatory framework. 'These important milestones will not only help us maintain and grow our presence in Europe but also advance and accelerate our broader Interventional Glaucoma initiatives globally. We are eager to commence commercial launch activities for these novel MIGS therapies over the coming months." Last year, the company began commercial launch activities for iDose TR, an intracameral procedural pharmaceutical that provides continuous glaucoma drug therapy inside the eye for extended periods. In 2023, speciality materials and chemical company Celanese entered an agreement with Glaukos for the supply of its VitalDose drug delivery platform. "Glaukos gains EU certification for iStent infinite and other MIGS devices" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Business Wire
25-06-2025
- Business
- Business Wire
Glaukos Announces EU MDR Certification for iStent infinite ® and Other Leading MIGS Therapies
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite ®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject ® W. Glaukos' iStent ® trabecular micro-bypass stenting platform primarily involves the insertion of a micro-scale surgical devices designed to reduce intraocular pressure by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma. "We are pleased to receive these important regulatory clearances for our leading trabecular micro-bypass stenting devices, marking our company's first approvals under the new EU regulatory framework,' said Thomas Burns, Glaukos chairman and chief executive officer. 'These important milestones will not only help us maintain and grow our presence in Europe but also advance and accelerate our broader Interventional Glaucoma initiatives globally. We are eager to commence commercial launch activities for these novel MIGS therapies over the coming months." These certifications affirm that iStent infinite and iStent inject W meet the stringent requirements of the EU MDR – a new, robust framework established to ensure high standards of quality, safety and effectiveness for medical devices marketed in the EU. Glaukos is proud to be the corporate pioneer and global market leader in MIGS, with its family of iStent technologies supported by nearly 400 peer-reviewed publications, 20 plus years of clinical and commercial experience and more than one million iStent devices implanted worldwide since its inception. The company believes it offers the industry's most comprehensive offering of minimally-invasive, tissue-sparing glaucoma solutions, supporting its goal to provide a full range of options to fit surgeons' individual glaucoma treatment algorithms that offer the most favorable short- and long-term benefit-to-risk calculus at every stage of disease progression, from ocular hypertension through refractory disease, and in both combo-cataract and standalone procedures. About Glaukos Glaukos ( is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose ® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases. About iStent infinite ® Trabecular Micro-Bypass System (U.S.) Indication for Use: The iStent infinite Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed. Contraindications: The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. Warnings: Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard. MRI Information: The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details. Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic. Adverse Events: The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%). Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events. For more information, visit
Yahoo
25-06-2025
- Business
- Yahoo
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies
Regulatory Clearances Support Glaukos' Plans to Advance and Accelerate its Interventional Glaucoma Initiatives Globally Marks the Company's First Regulatory Clearances Under the New EU Regulatory Framework ALISO VIEJO, Calif., June 25, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite®, along with several of its other leading micro-invasive glaucoma surgery (MIGS) technologies, including iStent inject® W. Glaukos' iStent® trabecular micro-bypass stenting platform primarily involves the insertion of a micro-scale surgical devices designed to reduce intraocular pressure by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma. "We are pleased to receive these important regulatory clearances for our leading trabecular micro-bypass stenting devices, marking our company's first approvals under the new EU regulatory framework," said Thomas Burns, Glaukos chairman and chief executive officer. "These important milestones will not only help us maintain and grow our presence in Europe but also advance and accelerate our broader Interventional Glaucoma initiatives globally. We are eager to commence commercial launch activities for these novel MIGS therapies over the coming months." These certifications affirm that iStent infinite and iStent inject W meet the stringent requirements of the EU MDR – a new, robust framework established to ensure high standards of quality, safety and effectiveness for medical devices marketed in the EU. Glaukos is proud to be the corporate pioneer and global market leader in MIGS, with its family of iStent technologies supported by nearly 400 peer-reviewed publications, 20 plus years of clinical and commercial experience and more than one million iStent devices implanted worldwide since its inception. The company believes it offers the industry's most comprehensive offering of minimally-invasive, tissue-sparing glaucoma solutions, supporting its goal to provide a full range of options to fit surgeons' individual glaucoma treatment algorithms that offer the most favorable short- and long-term benefit-to-risk calculus at every stage of disease progression, from ocular hypertension through refractory disease, and in both combo-cataract and standalone procedures. About Glaukos Glaukos ( is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rarely diagnosed corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases. About iStent infinite® Trabecular Micro-Bypass System (U.S.) Indication for Use: The iStent infinite Trabecular Micro-Bypass System Model iS3 is an implantable device intended to reduce the intraocular pressure (IOP) of the eye. It is indicated for use in adult patients with primary open-angle glaucoma in whom previous medical and surgical treatment has failed. Contraindications: The iStent infinite is contraindicated in eyes with angle-closure glaucoma where the angle has not been surgically opened, acute traumatic, malignant, active uveitic, or active neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. Warnings: Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization that could lead to improper placement of the stent and pose a hazard. MRI Information: The iStent infinite is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details. Precautions: The surgeon should monitor the patient postoperatively for proper maintenance of IOP. Three out of 61 participants (4.9%) in the pivotal clinical trial were phakic. Therefore, there is insufficient evidence to determine whether the clinical performance of the device may be different in those who are phakic versus in those who are pseudophakic. Adverse Events: The most common postoperative adverse events reported in the iStent infinite pivotal trial included IOP increase ≥ 10 mmHg vs. baseline IOP (8.2%), loss of BSCVA ≥ 2 lines (11.5%), ocular surface disease (11.5%), perioperative inflammation (6.6%) and visual field loss ≥ 2.5 dB (6.6%). Caution: Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events. For more information, visit View source version on Contacts Chris LewisVice President, Investor Relations & Corporate Affairs(949) 481-0510clewis@
Miami Herald
10-03-2025
- Business
- Miami Herald
The Wallace Firm Names Thomas Burns as First Partner in Firm's 9+ Year History
Accomplished trial lawyer, Thomas Burns, recognized for exceptional track record and strategic litigation expertise. LOS ANGELES, CALIFORNIA / ACCESS Newswire / March 10, 2025 / The Wallace Firm proudly announces Thomas Burns as its first named Partner in the firm's 9+ year history, marking a major milestone in its growth and continued success. Since joining The Wallace Firm in 2020, Burns has built an impressive track record of plaintiff results, securing numerous six- and seven-figure verdicts and settlements, with total case results reaching the mid-to-high eight figures. With nearly a decade of experience as a serious injury trial lawyer -on both the defense and plaintiff sides-Tom brings a unique strategic advantage to the firm's high-stakes litigation. Recognized by Super Lawyers Magazine as a "Southern California Rising Star" for the fourth consecutive year (2022-2025), Burns has achieved significant outcomes in serious injury and wrongful death cases by successfully opposing summary judgment motions, tirelessly obtaining critical evidence, and thriving in jury trials. This is a defining moment for our firm," said Bradley Wallace, Founder of The Wallace Firm. "Tom's leadership, legal expertise, and unwavering commitment to justice have helped shape our success. His promotion to Partner is a testament to the incredible work he's done and the bright future ahead for The Wallace Firm. Burns' promotion reinforces The Wallace Firm's mission to deliver exceptional results for clients while continuing to grow as a leader in serious injury and wrongful death litigation. Founded in 2016 by Bradley Wallace, The Wallace Firm is a premier personal injury and wrongful death law firm headquartered in Los Angeles, California. Dedicated to providing relentless advocacy and achieving outstanding results, the firm has built a reputation for excellence through compassionate client service and a commitment to justice. Specializing in serious injury, wrongful death, and complex litigation, The Wallace Firm continues to expand its impact, driven by a team of skilled attorneys passionate about making a difference. For more information, visit Contact Information Angel Martinez angel@ (818) 476-5998 SOURCE: The Wallace Firm, PC press release
